Corpus ID: 24962604

Ergotamine tartrate and dihydroergotamine mesylate: safety profiles.

@article{Lipton1997ErgotamineTA,
  title={Ergotamine tartrate and dihydroergotamine mesylate: safety profiles.},
  author={Richard B. Lipton},
  journal={Headache},
  year={1997},
  volume={37 Suppl 1},
  pages={
          S33-41
        }
}
  • Richard B. Lipton
  • Published 1997
  • Medicine
  • Headache
  • Ergotamine tartrate (ET) and dihydroergotamine mesylate (DHE) have been widely and effectively used in the treatment of migraine for many decades, although few randomized, controlled clinical trials have been conducted with these compounds. To compare their safety profiles, the world literature on the two agents was surveyed. The results are summarized, along with a critical analysis of the strengths and limitations of the various sources of safety data (in vitro research, animal studies, Phase… CONTINUE READING

    Citations

    Publications citing this paper.
    SHOWING 1-10 OF 23 CITATIONS, ESTIMATED 75% COVERAGE

    Dihydroergotamine: role in the treatment of migraine

    VIEW 3 EXCERPTS
    CITES BACKGROUND

    Toxicological Assessment of Dihydroergotamine after Chronic Inhalation in Dogs

    VIEW 5 EXCERPTS
    CITES BACKGROUND & METHODS
    HIGHLY INFLUENCED

    The impact of ergotamine-induced headache and ergotamine withdrawal on information processing

    VIEW 5 EXCERPTS
    CITES BACKGROUND
    HIGHLY INFLUENCED

    Canadian Headache Society Guideline: acute drug therapy for migraine headache.

    FILTER CITATIONS BY YEAR

    1999
    2019

    CITATION STATISTICS

    • 2 Highly Influenced Citations